Mankind Pharma

[00:00:04] [SPEAKER_00]: Hello everyone! Welcome to the latest episode of Har Stock Kuch Kehta Hai, presented by Angel

[00:00:09] [SPEAKER_00]: One. A podcast where we will know and understand how a company's journey is.

[00:00:16] [SPEAKER_00]: We hope you enjoyed our previous episodes. If you are listening to this podcast for the

[00:00:21] [SPEAKER_00]: first time, then we would recommend that you do check out our previous episodes as

[00:00:24] [SPEAKER_00]: well, where we talked about United Breweries, ITC, Pryments, Indigo Airlines and Jilet India

[00:00:31] [SPEAKER_00]: Limited. My name is Rohan, and let's start today's episode.

[00:00:46] [SPEAKER_00]: So here is the story of 1995. Mr. Ramesh Duneja and his brother Mr. Rajiv Duneja established

[00:00:53] [SPEAKER_00]: Mankind Pharma in New Delhi and today is the fourth largest pharmaceutical company in

[00:00:59] [SPEAKER_00]: India. In the beginning, the company started manufacturing generic medicines and over-the-counter

[00:01:02] [SPEAKER_00]: products. It was meant to provide affordable healthcare for the entire society. Mankind Pharma

[00:01:10] [SPEAKER_00]: has seen consistent growth and expansion in its journey. Its strategy was to focus on

[00:01:15] [SPEAKER_00]: quality and affordable pricing, which greatly improved its business. Its innovative marketing

[00:01:22] [SPEAKER_00]: techniques helped them to capture Indian market. In 2005, the company entered the off-thalmic

[00:01:29] [SPEAKER_00]: pharma sector with the launch of iDrops. In 2007, the company launched its brand Manforce

[00:01:38] [SPEAKER_00]: in consumer healthcare. Mankind Pharma initially adopted a unique approach to strengthen

[00:01:41] [SPEAKER_00]: its distribution network. Big cities like Mumbai and Delhi instead of targeting

[00:01:50] [SPEAKER_00]: their products to rural areas, and this increased its reach and sales. Mankind Pharma expanded

[00:01:58] [SPEAKER_00]: its operations and made its footprint in the international market. In 2005, its sales

[00:02:06] [SPEAKER_00]: increased from 5 crores to 500 crores and in 2016, it increased to 5000 crores. Due to

[00:02:13] [SPEAKER_00]: deep market penetration, the company is growing both India and abroad.

[00:02:20] [SPEAKER_00]: Let's look at their competition. The main competitors of Mankind Pharma are Sun Pharmaceuticals,

[00:02:29] [SPEAKER_00]: DVs, Laboratories and Nectopharma. With around 25 factories, Mankind Pharma manufactures

[00:02:36] [SPEAKER_00]: more than 1000 products under an umbrella of 36 brands. All these medicines help to

[00:02:42] [SPEAKER_00]: cure pain, infections and cardiac disease. This is the first time in a company that

[00:02:46] [SPEAKER_00]: offers its own homegrown brands of consumer healthcare products, like condoms, pregnancy

[00:02:54] [SPEAKER_00]: tests and acne treatments. The company has 6 R&D centres with more than 600 scientists.

[00:03:02] [SPEAKER_00]: Now let's get into this industry. The Indian pharmaceutical industry plays an important

[00:03:09] [SPEAKER_00]: role in the global pharmaceutical industry. From 2018 to 2023, the Indian pharmaceutical

[00:03:16] [SPEAKER_00]: industry has grown from 6-8% CAGR, which is primarily due to the expansion of

[00:03:22] [SPEAKER_00]: increased and domestic markets in exports. India's domestic pharmaceutical sector

[00:03:27] [SPEAKER_00]: was valued at $42 billion in 2021. We are global medical tourism hub as well

[00:03:39] [SPEAKER_00]: as the world's largest supply of low-cost vaccines in the world.

[00:03:44] [SPEAKER_00]: Let's look at Mankind Pharma's financial performances.

[00:03:48] [SPEAKER_00]: For the fourth quarter of the year, Mankind Pharma has reported a consolidated net profit

[00:03:57] [SPEAKER_00]: of Rs. 477 crore, which has been 62.2% since last year. The company's revenue from

[00:04:03] [SPEAKER_00]: operations was Rs. 2,441 crore, up by 19% year on year from Rs. 2,053 crore in the same

[00:04:11] [SPEAKER_00]: period last year. The company has also reduced its expenses. The expenses in this quarter

[00:04:17] [SPEAKER_00]: were Rs. 1,964 crore versus Rs. 2,199 crore in October-December quarter.

[00:04:25] [SPEAKER_00]: So now let's talk about the financial performance. Let's talk about Mankind Pharma's

[00:04:30] [SPEAKER_00]: key CSR initiatives. Most of the company's CSR initiatives focus on health, education

[00:04:36] [SPEAKER_00]: and livelihood enhancement initiatives. Mankind Pharma supports such non-profit

[00:04:42] [SPEAKER_00]: organizations that are involved in the conservation of healthcare facilities, social welfare,

[00:04:47] [SPEAKER_00]: education and natural resources. Some of the key CSR initiatives are socio-economic

[00:04:54] [SPEAKER_00]: upliftment, company-society upliftment, especially education, healthcare and skill development.

[00:05:01] [SPEAKER_00]: Healthcare and education. Mankind Pharma provides healthcare and education facilities for

[00:05:08] [SPEAKER_00]: underprivileged children. Looking ahead, Mankind Pharma is focusing on

[00:05:11] [SPEAKER_00]: growing rapidly in the domestic market. Especially in the chronic segment

[00:05:15] [SPEAKER_00]: and consumer healthcare business, the company is committed to ethical, just

[00:05:20] [SPEAKER_00]: and ecologically conscious operations adhering to environmental, social and governance principles.

[00:05:31] [SPEAKER_00]: With this, we come to the end of this episode. Thank you so much for listening to us.

[00:05:36] [SPEAKER_00]: We hope you liked this episode. If yes, then please do share it with your friends

[00:05:41] [SPEAKER_00]: and family. We will bring a new story behind the company every week through this

[00:05:50] [SPEAKER_00]: episode.